The development of a mass spectrometry technical quality assurance program for detecting human disease-associated proteins (Proteomics)

This page provides information related to the project.

Page last updated: 11 December 2019

The project aimed to test the technical ability of laboratories to accurately detect disease-associated protein targets (biomarkers) using the high-throughput sensitive techniques of mass spectrometry. This is a new field of technology for pathology testing and in clinically diagnosing disease tissue. Disease-specific biomarker proteins are found in blood serum and urine, which will allow for non-invasive procedures to be undertaken via protein mass spectrometry for diagnostic analysis in Australian laboratories. The development of a quality assurance program for the successful monitoring and testing is required for this use of technology.

Proteomic testing in disease pathology is growing and represents an essential system to determine key underlying molecular mutations in the diseased proteins.

The development of a mass spectrometry technical quality assurance program for detecting human disease-associated proteins (Proteomics) (PDF 1369 KB)
The development of a mass spectrometry technical quality assurance program for detecting human disease-associated proteins (Proteomics) (Word 191 KB)